On October 15, 2025, Swissmedic announced a batch recall of the veterinary medicine Nobivac DHPPi, a lyophilisate designed for the preparation of an injectable suspension for dogs. The recall impacts batch number A777B01 and extends up to the retail level. This step has been taken in adherence to strict regulatory standards to ensure animal health and safety. Veterinary clinics, distributors, and pharmacies are advised to take immediate action to prevent further distribution or administration of the affected product.
What changed?
The recall targets batch A777B01 of Nobivac DHPPi, a vaccine indicated for dogs to provide immunization against canine distemper, hepatitis, parvovirus, and parainfluenza infections. The recall was initiated based on concerns regarding product quality identified through post-market surveillance.
The lyophilisate is used to create an injectable suspension, making it crucial for canine health. This recall highlights the importance of continuous monitoring and strict adherence to quality standards within the veterinary pharmaceutical industry.
Who is affected?
This recall primarily impacts entities involved in the distribution and administration of the specific batch, including:
- Veterinary clinics.
- Animal hospitals and practices.
- Retail outlets specializing in veterinary medicines.
- Distributors handling veterinary products.
Veterinarians and distributors should check their stocks and immediately isolate batch A777B01 of Nobivac DHPPi from inventory. Dog owners should consult their veterinarian if their pets have recently received this vaccine.
Next steps for compliance
What should distributors and retailers do?
All stakeholders handling the affected batch must immediately cease its distribution and sale. The batch should be quarantined and reported to Swissmedic for appropriate disposal instructions.
What should veterinary professionals do?
Clinicians should verify their inventory to ensure none of the impacted products are in use. If any doses from batch A777B01 have already been administered, veterinarians should monitor the animals closely for any adverse effects and document any findings comprehensively for submission to Swissmedic.
Frequently Asked Questions
A1: Check the batch number printed on the product packaging. If it matches A777B01, follow the recall steps outlined by Swissmedic.
A2: Veterinary professionals can provide guidance on alternative products suitable for canine vaccinations. Consult your veterinarian promptly for recommendations.
A3: If your dog has been vaccinated with the affected batch, schedule a veterinary appointment for a health check. Monitor your pet for any unusual symptoms and inform the veterinarian accordingly.
Conclusion
The recall of Nobivac DHPPi batch A777B01 demonstrates Swissmedic’s commitment to upholding strict regulatory standards and protecting canine health. Stakeholders are urged to act swiftly to comply with the recall instructions and communicate with their respective regulatory bodies or veterinarians regarding next steps.
Disclaimer
This information is intended for professionals working in veterinary care, retail, or regulatory sectors. It is not legal advice. Consult Swissmedic or other relevant authorities for further guidance.
Swissmedic notice
For full information about the Swissmedic announcement, see the link below.
https://www.swissmedic.ch/swissmedic/en/home/tierarzneimittel/veterinary-medicines/batch-recalls-veterinary-medicines/chargenrueckruf-nobivac-dhppi-ad-us-vet-lyophilisat-injsusp-hunde.html